date:Nov 30, 2018
ISADE Group of Clinical Investigators.
Participants ranged in age from 4 to 55 years. All had documented peanut allergies with a challenge dose: of 100 mg of less of peanut protein, which is the amount in one third of a peanut kernel.
The drug used in the study is called AR101. It is a peanut-derived investigational biologic oral immunotherapy drug. When a patient successfully completed the regimen, receiving 300 mg a day for 24 weeks, then were placed into a double-blind, placebo-control food